Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fluorescein sodium + proparacaine hydrochloride is a combination **small-molecule ophthalmic solution** that pairs the diagnostic dye fluorescein sodium with the topical local anesthetic proparacaine hydrochloride. The product is used as an ophthalmic drop when both corneal surface anesthesia and fluorescein staining are needed during eye procedures such as tonometry, gonioscopy, foreign body or suture removal, and short corneal or conjunctival procedures. Fluorescein sodium acts as a topical ophthalmic disclosing agent by fluorescing in the presence of aqueous tear film and highlighting corneal epithelial defects, while proparacaine hydrochloride provides rapid local anesthesia by reversibly blocking voltage-gated sodium channel-dependent nerve impulse conduction in sensory nerves. Historical marketed products include Flucaine and Fluorocaine, with manufacturing associated with Altaire Pharmaceuticals and prior distribution associated with OCuSOFT; the formulation has been described as an unapproved ophthalmic drug product in the United States.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on fluorescein sodium + proparacaine hydrochloride.